Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
Authors
Keywords
Platinum-resistant ovarian cancer, DNA repair, CCNE1 amplification, Homologous recombination deficiency, Resistance mechanisms
Journal
SEMINARS IN CANCER BIOLOGY
Volume 77, Issue -, Pages 29-41
Publisher
Elsevier BV
Online
2020-11-06
DOI
10.1016/j.semcancer.2020.10.016
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The evolutionary history of 2,658 cancers
- (2020) Moritz Gerstung et al. NATURE
- Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
- (2020) Min Chul Choi et al. Cancer Research and Treatment
- Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin
- (2020) Marta Mariniello et al. Cancers
- Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
- (2020) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer
- (2020) Guanghui Gong et al. Journal of Ovarian Research
- Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
- (2020) Sanghoon Lee et al. Cell Reports
- Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
- (2020) Aline Talhouk et al. CLINICAL CANCER RESEARCH
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
- (2019) Deborah Porto Cotrim et al. BMC CANCER
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
- (2019) Jingyan Yi et al. EBioMedicine
- Translating insights into tumor evolution to clinical practice: promises and challenges
- (2019) Matthew W. Fittall et al. Genome Medicine
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Exploiting DNA Replication Stress for Cancer Treatment
- (2019) Tajinder Ubhi et al. CANCER RESEARCH
- Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity
- (2019) Clara Bodelon et al. CLINICAL CANCER RESEARCH
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
- (2019) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
- (2019) Adriaan Vanderstichele et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
- (2019) Gwenael Ferron et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
- (2019) Charlie Gourley et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Intrinsic Resistance to MEK Inhibition Through BET Protein Mediated Kinome Reprogramming in NF1-deficient Ovarian Cancer
- (2019) Alison M Kurimchak et al. MOLECULAR CANCER RESEARCH
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
- (2019) Anastasia De Luca et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
- (2019) Gerald S. Falchook et al. CLINICAL CANCER RESEARCH
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies
- (2019) Mohammad Mirza-Aghazadeh-Attari et al. DNA REPAIR
- The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
- (2019) Musaffe Tuna et al. BRITISH JOURNAL OF CANCER
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility
- (2019) Julia E. Fehniger et al. GYNECOLOGIC ONCOLOGY
- Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy
- (2019) Chul Won Yun et al. Cells
- Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
- (2018) Hélène Marijon et al. BIOMEDICINE & PHARMACOTHERAPY
- Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
- (2018) Kristina Lindemann et al. GYNECOLOGIC ONCOLOGY
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
- (2018) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy
- (2018) Yue-Qin Li et al. IUBMB LIFE
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- Beyond PARP—POLθ as an anticancer target
- (2018) Geoff S. Higgins et al. SCIENCE
- Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
- (2018) Katherine Sullivan-Reed et al. Cell Reports
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
- (2018) Diar Aziz et al. GYNECOLOGIC ONCOLOGY
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
- (2018) Bhanvi Mishra et al. CANCER BIOLOGY & THERAPY
- Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
- (2018) Alison E. Freimund et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
- (2018) Sara J. Dubbury et al. NATURE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- The control of DNA repair by the cell cycle
- (2017) Nicole Hustedt et al. NATURE CELL BIOLOGY
- Non-homologous DNA end joining and alternative pathways to double-strand break repair
- (2017) Howard H. Y. Chang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Epigenetics in ovarian cancer
- (2017) Yanina Natanzon et al. SEMINARS IN CANCER BIOLOGY
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
- (2017) Katharina Prieske et al. Oncotarget
- CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
- (2017) Josephine B. Walton et al. Scientific Reports
- A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
- (2016) MoonSun Jung et al. CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
- (2016) Joanne Kotsopoulos et al. GYNECOLOGIC ONCOLOGY
- Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification
- (2016) Gottfried E. Konecny et al. GYNECOLOGIC ONCOLOGY
- BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
- (2016) Philipp Harter et al. GYNECOLOGIC ONCOLOGY
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
- (2016) Yifan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- The Fanconi anaemia pathway: new players and new functions
- (2016) Raphael Ceccaldi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
- (2016) Eva Dombi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51
- (2015) Ambber Ward et al. CANCER TREATMENT REVIEWS
- Nucleotide excision repair in humans
- (2015) Graciela Spivak DNA REPAIR
- Efficient molecular subtype classification of high-grade serous ovarian cancer
- (2015) Huei San Leong et al. JOURNAL OF PATHOLOGY
- The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene
- (2015) Michael M. Gottesman et al. JNCI-Journal of the National Cancer Institute
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- An integrated map of structural variation in 2,504 human genomes
- (2015) Peter H. Sudmant et al. NATURE
- The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene
- (2015) Michael M. Gottesman et al. JNCI-Journal of the National Cancer Institute
- Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations
- (2015) Navneet Sangha et al. NEOPLASIA
- Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian Cancer
- (2014) C. Wang et al. CANCER RESEARCH
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- Prognosis and Conditional Disease-Free Survival Among Patients With Ovarian Cancer
- (2014) Michelle L. Kurta et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Large Inverted Duplications in the Human Genome Form via a Fold-Back Mechanism
- (2014) Karen E. Hermetz et al. PLoS Genetics
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
- (2012) Z. C. Wang et al. CLINICAL CANCER RESEARCH
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
- (2012) Jessica N McAlpine et al. MODERN PATHOLOGY
- Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress
- (2012) R M Jones et al. ONCOGENE
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- "Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
- (2010) N. Chan et al. CLINICAL CANCER RESEARCH
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started